The use of infliximab for the treatment of non-specific ulcerative colitis: the cases of postpartum clinical course of the disease

Beliatko E.A.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova

Shifrin O.S.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova

The use of infliximab for the treatment of non-specific ulcerative colitis: the cases of postpartum clinical course of the disease

Authors:

Beliatko E.A., Shifrin O.S.

More about the authors

Journal: Russian Journal of Evidence-Based Gastroenterology. 2012;(2): 83‑88

Downloaded: 48

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Beliatko EA, Shifrin OS. The use of infliximab for the treatment of non-specific ulcerative colitis: the cases of postpartum clinical course of the disease. Russian Journal of Evidence-Based Gastroenterology. 2012;(2):83‑88. (In Russ.)

Подписка 2025 (Russian Journal of Evidence-Based Gastroenterology)

Close metadata

Recommended articles:

An aggressive variant of Crohn’s disease in a teenage girl. (Case report). Russian Journal of Evidence-Based Gastroenterology. 2024;(1):115-120

Maintenance immunosuppressive therapy for Crohn’s disease: patient adherence and its impact on treatment efficacy. Case report. Russian Journal of Evidence-Based Gastroenterology. 2024;(2):90-96

Awareness of primary care physicians about inflammatory bowel diseases in the Chelyabinsk region. Russian Journal of Preventive Medicine. 2024;(5):38-45

Modern treatment of perianal fistulas following Crohn’s disease. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2024;(2):49-56

Influence of diagnostic period on the outcomes in patients with Crohn’s disease. Pirogov Russian Journal of Surgery. 2024;(7):36-44

Ulcerative colitis, similar to Crohn's disease, is known to belong to a group of diseases underlain by disturbances of the autoimmune mechanisms maintaining the integrity of the intestinal mucous membrane. The authors describe two clinical cases of this pathology and provide the scientific substantiation for its conservative treatment with the use of infliximab as one of the most efficacious therapeutic modalities for the women presenting with severe steroid-resistant non-specific ulcerative colitis that becomes clinically manifested during the postpartum period. It is emphasized that the management of such patients necessitates the involvement of surgeons, besides gastroenterologists, to guarantee the salvage of patients by colectomy in case they cease to respond to conservative therapy.

Keywords:

non-specific ulcerative colitis

Crohn's disease

infliximab

colectomy

Authors:

Beliatko E.A.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova

Shifrin O.S.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova

List of references:

Ratsional'naya farmakoterapiya zabolevanii organov pishchevareniya (rukovodstvo dlya praktikuyushchikh vrachei). Pod red. V.T. Ivashkina. M: Litterra 2003: 259-262.
Uchebnoe posobie po gastroenterologii. Pod red. G.E. Roitberg, A.V. Strutynskogo M: MEDpress-inform 2007; 461.
Lichtenstein G.R. et al. The Clinician's Guide to Inflamatory Bowel Disease. SLAK Incorporated-USA 2003: 183-184.
Adler G. Bolezn' Krona i yazvennyi kolit. M: GEOTAR-Med 2001: 52-57.
Faubion W.J., Loftus E.J., Harmsen W. et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-260.
Munkholm P., Langholz E., Davidsen M., Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-362.
Steinhart H. Maintenance therapy in Crohn's disease. Can J Gastroenterol Update Liver Inflammatory Bowel Dis (ULIBD) 2000; 14: 23-28.
Sandborn W., Sutherland L., Pearson D. et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000; 2: CD000545.
Feagan B., Rochon J., Fedorak R. et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332: 292-297.
Kindler V., Sappino A., Grau G. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 731-740.
Braegger C., Nicholls S., Murch S. et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89.
Beese E., Michie C., Nicholls S. et al. Tumor necrosis factor alphaproducing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106: 1455-1466.
MacDonald T., Hutchings P., Choy M. et al. Tumor necrosis factor-alpha and interferon gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990; 81: 301-305.
Schreiber S., Nikolaus S., Hampe J. et al. Tumour necrosis factor and interleukin 1 in relapse of Crohn's disease. Lancet 1999; 353: 459-461.
Knight D.M., Trinh H., Le J. et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443-1453.
Targan S.R., Hanauer S.B., van Deventer S.J. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997; 337: 1029-1035.
Cohen R., Tsang J., Hanauer S. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000; 95: 3469-3477.
Ricart E., Panaccione R., Loftus E. et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001; 96: 722-729.
Nikolaus S., Raedler A., Kuhbacher T. et al. Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000; 356: 1475-1479.
Rutgeerts P., D'Haens G., Targan S. et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) tomaintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-769.
Best W., Becktel J., Singleton J., Kern F.J. Development of a Crohn's Disease Activity Index: National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-444.
Irvine E., Feagan B., Rochon J. et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994; 106: 287-296.
Gornet J., Hassani Z., Allez M., Sabate J., Modigliani R., Lemann M. Infliximab in Refractory Ulcerative Colitis. Gastroenterology unit, Saint-Louis hospital, Paris, 2009.
Ording Olsen K., Juul S., Berndtsson I. et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 2002; 122:15-19.
Hahnloser D., Pemberton J.H., Wolff B.G. et al. The effect of aging on function and quality of life in ileal pouch patients: a single cohort experience of 409 patients with chronic ulcerative colitis. Ann Surg 2004; 240: 615-621.
Hove T., van Montfrans C., Peppelenbosch M.P., van Deventer S.J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50: 206-211.

Close metadata